Eric Benevich, Chief Commercial Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 150,000 shares at $139.38 ($20.9M) on 2024-03-14, disclosed to the SEC on 2024-03-15.
Scheduled sale ($20.9M) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $139.38 | 5,479 | $764K | 3.7% |
| 2 | $139.38 | 5,479 | $764K | 3.7% |
| 3 | $139.38 | 69,521 | $9.7M | 46.3% |
| 4 | $139.38 | 69,521 | $9.7M | 46.3% |
| Total | $139.38 avg | 150,000 | $20.9M | 100% |
| Filing → |
| NBIX | SELL | 2025-02-14 | $503K | — | Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $369K | — | Filing → |